Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dagmar Taeuscher"'
Autor:
Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8127-8137 (2021)
Abstract Background Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐pac
Externí odkaz:
https://doaj.org/article/5b6b2c18b24b4eb19418ef882658d450
Autor:
Tobias Dechow, Jorge Riera‐Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Ursula Oppermann, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke, Dagmar Taeuscher, Manfred Welslau, Karin Potthoff
Publikováno v:
International Journal of Cancer. 153:141-152
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d66c57c784f50aeed18c3e26fa82752d
https://doi.org/10.1002/ijc.34467
https://doi.org/10.1002/ijc.34467
Autor:
Jan Janssen, Axel Nacke, Stephan Budweiser, Karin Potthoff, Tobias Dechow, Holger Schulz, Manfred Welslau, Björn Hackanson, Marco Chiabudini, Dagmar Taeuscher, Jorge Riera-Knorrenschild, Ludwig Fischer von Weikersthal
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 22, Pp 8127-8137 (2021)
Cancer Medicine, Vol 10, Iss 22, Pp 8127-8137 (2021)
Background Platinum‐based chemotherapy remains a first‐line standard of care for approximately 30% of patients with non‐small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab‐paclitaxel/c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea860233ce9ea5bc385e00291961b76d
https://pubmed.ncbi.nlm.nih.gov/34668662
https://pubmed.ncbi.nlm.nih.gov/34668662
Autor:
Mathias Cebulla, Heinz-Erich Wichmann, Karl Haeußinger, You-Dschun Ko, Andreas Groeschel, Heike Bickeboeller, Gabi Woelke, Kirstin Mittelstrass, Jenny Chang-Claude, Maria Degen, Peter Drings, Wilhelm Schmidt, Norman Klopp, Eckart Meese, Gerd Hoeffken, Wiebke Sauter, Hendrik Dienemann, Harald Morr, Dagmar Taeuscher, Angela Risch, Maria Timofeeva, Thomas Illig, Karsten grosse Kreymborg, Gerhard W. Sybrecht, Christine Schmidt, Albert Rosenberger, Bettina Jilge
Publikováno v:
BMC Cancer, Vol 8, Iss 1, p 113 (2008)
BMC Cancer
BMC Cancer 8:113 (2008)
BMC Cancer
BMC Cancer 8:113 (2008)
The polymorphism SNP309 (rs2279744) in the promoter region of the MDM2 gene has been shown to alter protein expression and may play a role in the susceptibility to lung cancer. The MDM2 protein is a key inhibitor of p53 and several mechanisms of MDM2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa075ac93bab7bf56d72bc4dc6baff8f